Page 56 - Exact Sciences News Today

UBS Group started coverage on shares of Exact Sciences (NASDAQ:EXAS – Get Rating) in a research note released on Friday morning, The Fly reports. The brokerage issued a neutral rating and a $73.00 target price on the medical research company’s stock. A number of other equities research analysts have also commented on EXAS. Cowen increased […]

Pictet & Cie Europe SA grew its position in Exact Sciences Co. (NASDAQ:EXAS – Get Rating) by 4.9% in the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 143,368 shares of the medical research company’s stock after purchasing an additional 6,655 shares during the period. Pictet & Cie Europe SA’s holdings in Exact Sciences were […]

Robeco Institutional Asset Management B.V. boosted its holdings in shares of Exact Sciences Co. (NASDAQ:EXAS – Get Rating) by 727.8% during the fourth quarter, HoldingsChannel reports. The fund owned 42,026 shares of the medical research company’s stock after purchasing an additional 36,949 shares during the quarter. Robeco Institutional Asset Management B.V.’s holdings in Exact Sciences […]

Regent Peak Wealth Advisors LLC cut its holdings in shares of Exact Sciences Co. (NASDAQ:EXAS – Get Rating) by 4.7% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 11,604 shares of the medical research company’s stock after selling 578 shares during the […]

Exact Sciences Co. (NASDAQ:EXAS – Get Rating) EVP Sarah Condella sold 1,000 shares of Exact Sciences stock in a transaction on Monday, May 1st. The stock was sold at an average price of $63.78, for a total transaction of $63,780.00. Following the completion of the sale, the executive vice president now owns 86,401 shares of […]

Detailed price information for Bausch Health Companies Inc (BHC-T) from The Globe and Mail including charting and trades.

Exact Sciences Co. (NASDAQ:EXAS – Get Rating) EVP Sarah Condella sold 1,000 shares of Exact Sciences stock in a transaction on Monday, May 1st. The shares were sold at an average price of $63.78, for a total value of $63,780.00. Following the completion of the sale, the executive vice president now owns 86,401 shares in […]

Exact Sciences Co. (NASDAQ:EXAS – Get Rating) has been assigned a consensus rating of “Moderate Buy” from the fourteen brokerages that are presently covering the firm, Marketbeat reports. Four investment analysts have rated the stock with a hold recommendation and eight have assigned a buy recommendation to the company. The average 1 year target price […]

MADISON, Wis., May 1, 2023 /PRNewswire/ -- Exact Sciences Corp. , a leading provider of cancer screening and diagnostic tests, today announced that company management will participate in the... | May 1, 2023

Westpac Banking Corp reduced its position in Exact Sciences Co. (NASDAQ:EXAS – Get Rating) by 10.4% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 142,455 shares of the medical research company’s stock after selling 16,512 shares during the quarter. […]